Arvinas (ARVN) to Release Earnings on Tuesday

Arvinas (NASDAQ:ARVN - Get Free Report) is expected to release its Q4 2024 earnings data before the market opens on Tuesday, February 11th. Analysts expect Arvinas to post earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period last year, the business posted ($2.53) earnings per share. On average, analysts expect Arvinas to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Arvinas Trading Up 1.5 %

ARVN stock traded up $0.27 during trading hours on Wednesday, hitting $17.95. 1,339,512 shares of the stock traded hands, compared to its average volume of 908,115. The stock has a 50-day simple moving average of $19.33 and a 200 day simple moving average of $23.36. The company has a market cap of $1.23 billion, a P/E ratio of -3.84 and a beta of 1.88. Arvinas has a one year low of $16.61 and a one year high of $53.08.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ARVN shares. BTIG Research initiated coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price objective on the stock. BMO Capital Markets restated an "outperform" rating and issued a $82.00 price target (down previously from $88.00) on shares of Arvinas in a research report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. Barclays reduced their price objective on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, Stephens began coverage on Arvinas in a research report on Monday, November 18th. They set an "overweight" rating and a $55.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $59.58.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.